 Connection
Eric Wu to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Eric Wu has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.662 |
|
|
|
-
Gu?rin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opin Pharmacother. 2016 Jun; 17(9):1189-96.
Score: 0.277
-
Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-na?ve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017 Feb; 20(2):121-128.
Score: 0.071
-
Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Gu?rin A. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Curr Med Res Opin. 2016; 32(2):385-94.
Score: 0.068
-
Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. Expert Opin Pharmacother. 2015; 16(14):2101-11.
Score: 0.066
-
Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Curr Med Res Opin. 2015 Aug; 31(8):1573-82.
Score: 0.066
-
Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin. 2015 Jun; 31(6):1095-103.
Score: 0.065
-
Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Gu?rin A. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Adv Ther. 2016 06; 33(6):983-97.
Score: 0.017
-
Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Gu?rin A. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. J Med Econ. 2016; 19(4):414-23.
Score: 0.017
-
Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer. J Comp Eff Res. 2015 Aug; 4(4):315-26.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|